RT Journal Article
T1 Direct-acting antivirals are effective and safe in HCV/HIV-coinfected liver transplant recipients who experience recurrence of hepatitis C: A prospective nationwide cohort study.
A1 Manzardo, Christian
A1 Londoño, Maria C
A1 Castells, LLuis
A1 Testillano, Milagros
A1 Luis Montero, Jose
A1 Peñafiel, Judit
A1 Subirana, Marta
A1 Moreno, Ana
A1 Aguilera, Victoria
A1 Luisa Gonzalez-Dieguez, Maria
A1 Calvo-Pulido, Jorge
A1 Xiol, Xavier
A1 Salcedo, Magdalena
A1 Cuervas-Mons, Valentin
A1 Manuel Sousa, Jose
A1 Suarez, Francisco
A1 Serrano, Trinidad
A1 Ignacio Herrero, Jose
A1 Jimenez, Miguel
A1 Fernandez, Jose R
A1 Gimenez, Carlos
A1 Del Campo, Santos
A1 Esteban-Mur, Juan I
A1 Crespo, Gonzalo
A1 Moreno, Asuncion
A1 de la Rosa, Gloria
A1 Rimola, Antoni
A1 Miro, Jose M
K1 Clinical research/practice
K1 Infection and infectious agents-viral
K1 Human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) 
K1 Liver transplantation
K1 Hepatitis C
AB Direct-acting antivirals have proved to be highly efficacious and safe in monoinfected liver transplant (LT) recipients who experience recurrence of hepatitis C virus (HCV) infection. However, there is a lack of data on effectiveness and tolerability of these regimens in HCV/HIV-coinfected patients who experience recurrence of HCV infection after LT. In this prospective, multicenter cohort study, the outcomes of 47 HCV/HIV-coinfected LT patients who received DAA therapy (with or without ribavirin [RBV]) were compared with those of a matched cohort of 148 HCV-monoinfected LT recipients who received similar treatment. Baseline characteristics were similar in both groups. HCV/HIV-coinfected patients had a median (IQR) CD4 T-cell count of 366 (256-467) cells/µL. HIV-RNA was <50 copies/mL in 96% of patients. The DAA regimens administered were SOF + LDV ± RBV (34%), SOF + SMV ± RBV (31%), SOF + DCV ± RBV (27%), SMV + DCV ± RBV (5%), and 3D (3%), with no differences between the groups. Treatment was well tolerated in both groups. Rates of SVR (negative serum HCV‐RNA at 12 weeks after the end of treatment) were high and similar for coinfected and monoinfected patients (95% and 94%, respectively; P = .239). Albeit not significant, a trend toward lower SVR rates among patients with advanced fibrosis (P = .093) and genotype 4 (P = .088)was observed. In conclusion, interferon‐free regimens with DAAs for post‐LT recurrence of HCV infection in HIV‐infected individuals were highly effective and well tolerated, with results comparable to those of HCV‐monoinfected patients.
PB Elsevier
YR 2018
FD 2018-08-13
LK http://hdl.handle.net/10668/12665
UL http://hdl.handle.net/10668/12665
LA en
NO Manzardo C, Londoño MC, Castells L, Testillano M, Luis Montero J, Peñafiel J, et al. Direct-acting antivirals are effective and safe in HCV/HIV-coinfected liver transplant recipients who experience recurrence of hepatitis C: A prospective nationwide cohort study. Am J Transplant. 2018 Oct;18(10):2513-2522
DS RISalud
RD Apr 9, 2025